Ridaifen-B

• Catalog No.: R5030
• CAS Number: 886465-70-9
• M. F.: C34H42N2O2
• M. W.: 510.70948
• Purity: ≥98% (HPLC)
• Storage: desiccated

SYNONYMS

• IUPAC name: 1-{2-[4-(2-phenyl-1-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}but-1-en-1-yl)phenoxy]ethyl}pyrrolidine
• IUPAC Traditional name: 1-{2-[4-(2-phenyl-1-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}but-1-en-1-yl)phenoxy]ethyl}pyrrolidine
• Synonyms: 1,1′-[(2-Phenyl-1-buten-1-ylidene)bis(4,1-phenyleneoxy-2,1-ethanediyl)]bis-pyrrolidine

DATABASE IDS

• MDL Number: MFCD11114395
• CAS Number: 886465-70-9

PROPERTIES

• Empirical Formula (Hill Notation): C34H42N2O2
• Purity: ≥98% (HPLC)
• Apperance: white solid
• Solubility: DMSO: ≥13 mg/mL
• Solubility: H2O: insoluble
• GHS Signal Word: Danger
• GHS Hazard statements: H315-H318-H335
• European Hazard Symbols: Irritant (Xi)
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves
• GHS Precautionary statements: P261-P280-P305 + P351 + P338
• Risk Statements: 37/38-41
• Safety Statements: 26-39
• Storage Condition: desiccated
• Storage Temperature: 2-8°C
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
Ridaifen-B (RID-B) is a novel tamoxifen (TAM) analog that significantly augments apoptosis-inducing effect of TAM in estrogen receptor (ER)-negatives cells. Ridaifen-B induces mitochondria-involved apoptosis in Jurkat cells, as evidenced by chromatin-condensed cells as well as downstream activation of caspases (caspase-3, -8 and -9) in a dose- and time-dependent manner. At 4 hours of incubation, IC50 for RID-B is 4 muM (30 muM for TAM). And at prolonged treatment of 48 hours, IC50 for RID-B is 0.1 muM.1 In a related report2 on the global anti-tumor activity, RID-B strongly inhibits 39 human cancer cells (JFCR 39), both ER-+ or ER-- at concentrations of equal or less than 1muM (e.g., at 0.38muM for SF-539 [central nervous system], at 0.58muM for HT-29 [colon], at 0.20muM for DMS114 [lung], at 0.21muM for LOX-IMVI [melanoma], and at 0.23muM for MKN74 [stomach]. The binding protein of RID-B that exerts the apoptosis events is currently under investigation.

Description (简体中文)

Biochem/physiol Actions
Ridaifen-B (RID-B) is a novel tamoxifen (TAM) analog that significantly augments apoptosis-inducing effect of TAM in estrogen receptor (ER)-negatives cells. Ridaifen-B induces mitochondria-involved apoptosis in Jurkat cells, as evidenced by chromatin-condensed cells as well as downstream activation of caspases (caspase-3, -8 and -9) in a dose- and time-dependent manner. At 4 hours of incubation, IC50 for RID-B is 4 muM (30 muM for TAM). And at prolonged treatment of 48 hours, IC50 for RID-B is 0.1 muM.1 In a related report2 on the global anti-tumor activity, RID-B strongly inhibits 39 human cancer cells (JFCR 39), both ER-+ or ER-- at concentrations of equal or less than 1muM (e.g., at 0.38muM for SF-539 [central nervous system], at 0.58muM for HT-29 [colon], at 0.20muM for DMS114 [lung], at 0.21muM for LOX-IMVI [melanoma], and at 0.23muM for MKN74 [stomach]. The binding protein of RID-B that exerts the apoptosis events is currently under investigation.